Spotlight

Aspen Neuroscience to Present at Future of Parkinson’s Disease Conference

by
PSG Graph 2

SAN DIEGO and AUSTIN, Texas, Nov. 30, 2023 /PRNewswire/ — This week, Aspen Neuroscience will present to the Parkinson’s community at the Future of Parkinson’s Disease conference, held November 30 – December 3, in Austin. The joint annual conference is hosted by the Parkinson’s Foundation and the Parkinson Study Group.  In addition to multiple scientific presentations, Aspen Chief Executive Officer Damien McDevitt, PhD, and co-founder and … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Cofounder Dr. Andrés Bratt-Leal Receives 2023 Biocom California Life Science Catalyst Award

by
Andrés Bratt Leal, PhD

SAN DIEGO, CALIF., November 21, 2023 – Biocom California, the association representing the California life sciences industry, has announced that Andrés Bratt-Leal, PhD, Aspen Neuroscience co-founder and senior vice-president of research and development, is a recipient of the 2023 Life Science Catalyst Awards. The winners will be honored in the Biocom California LifeLines digital platform, … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

FDA Grants Fast Track Designation to ANPD001, Autologous Investigational Cell Therapy for the Treatment of Parkinson’s Disease

by
cellimage001

SAN DIEGO, Oct. 19, 2023 /PRNewswire/ — Aspen Neuroscience today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ANPD001 for the treatment of Parkinson’s disease (PD) to improve motor function. ANPD001, is a personalized (autologous) cell therapy under investigation to treat PD by replacing lost dopamine neurons. The purpose of Fast … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience to Present at 2023 Cell & Gene Meeting on the Mesa

by
Untitled design 3

SAN DIEGO, Oct. 9, 2023 /PRNewswire/ — Aspen Neuroscience announced today that Chief Technology Officer Kim Raineri and Chief Scientific Officer Xiaokui Zhang, Ph.D. will present at the annual Cell & Gene Meeting on the Mesa, held this week in Carlsbad, Calif. and live-streamed globally. CTO Kim Raineri will present a corporate overview of Aspen Neuroscience, highlighting its work in the development of iPSC-derived … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience to Partner with Rune Labs and Emerald Innovations to Incorporate both Active and Passive Digital Health Monitoring in Trial Ready Cohort Screening Study

by
Untitled design 1

Screening Study to Include Multiple Objective Measures of Active and Passive Symptom Capture from Parkinson’s Disease Impact on Motor Function SAN DIEGO, Aug. 24, 2023 /PRNewswire/ —  Aspen Neuroscience today announced that it is partnering with Emerald Innovations, a pioneer in the creation of “invisible” off-body sensors for measuring health analytics, and Rune Labs, a software and … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces FDA Clearance of Investigational New Drug Application for ANPD001, Autologous Cell Therapy for the Treatment of Parkinson’s Disease

by
cellimage001

Aspen Will Initiate First Multicenter Phase 1/2a Clinical Trial of an Autologous iPSC Based Therapy in the U.S. SAN DIEGO, Aug. 8, 2023 /PRNewswire/ — Aspen Neuroscience today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, enabling the company to proceed with a clinical trial for ANPD001, a personalized … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Preclinical Safety and Efficacy Data for ANPD001 Presented by Dr. Andres Bratt-Leal at 2023 World Parkinson Congress in Barcelona

by
Andrés Bratt Leal, PhD

SAN DIEGO, July 6, 2023 /PRNewswire/ — On Wednesday at the 2023 World Parkinson Congress in Barcelona, Aspen Neuroscience co-founder Andres Bratt-Leal, PhD, Senior Vice President Research & Development, presented preclinical safety and efficacy data for the first time for ANPD001, Aspen’s iPSC-derived lead candidate for treatment of Parkinson’s Disease (PD). Dr. Bratt-Leal’s poster presentation, “Preclinical Safety and Efficacy of Dopamine … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Dr. Andres Bratt-Leal to Present Preclinical Safety and Efficacy Data for ANPD001 at the 2023 World Parkinson Congress in Barcelona

by
wpc2023 logo color scaled

SAN DIEGO, June 29, 2023 /PRNewswire/ — Next week at the upcoming World Parkinson Congress (WPC) 2023 in Barcelona, Spain, Aspen Neuroscience co-founder Andres Bratt-Leal, PhD, Senior Vice President, Research and Development, will present preclinical safety and efficacy data for the first time for ANPD001, Aspen’s iPSC-derived lead candidate for treatment of Parkinson’s Disease (PD). “Preclinical Safety and Efficacy of Dopamine … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Dr. Andrés Bratt-Leal to Present at the 2023 International Society for Stem Cell Research Annual Meeting Focus Sessions

by
Andres ISSCR

SAN DIEGO, June 14, 2023 /PRNewswire/ — Today Aspen Neuroscience, Inc. co-founder and Senior Vice President, Research & Development, Andrés Bratt-Leal, PhD, will present “Enabling Autologous iPSC-Derived Cell Therapies with Predictive Genomics,” during the Focus Sessions taking place during this week’s 2023 International Society for Stem Cell Research (ISSCR) Annual Meeting in Boston, Mass. His presentation will cover experiences … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Chief Scientific Officer Xiaokui Zhang Profiled in Insights Care Magazine

by
ProjectLogojpg

Our Chief Scientific Officer, Xiaokui Zhang, PhD, was profiled in the Insights Care article titled, “Xiaokui Zhang: Nurturing Healthcare Through Innovative Leadership.” The article can be found here: https://insightscare.com/xiaokui-zhang-nurturing-healthcare-through-innovative-leadership/

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Logo

Aspen Neuroscience leverages stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.

Contact

10835 Road to the Cure
Ste. 100
San Diego, CA 92121

© 2025 Aspen Neuroscience - All Rights Reserved